KR102174763B1 - 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커 - Google Patents

텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커 Download PDF

Info

Publication number
KR102174763B1
KR102174763B1 KR1020157017235A KR20157017235A KR102174763B1 KR 102174763 B1 KR102174763 B1 KR 102174763B1 KR 1020157017235 A KR1020157017235 A KR 1020157017235A KR 20157017235 A KR20157017235 A KR 20157017235A KR 102174763 B1 KR102174763 B1 KR 102174763B1
Authority
KR
South Korea
Prior art keywords
cancer
percentile
cells
cell
telomere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157017235A
Other languages
English (en)
Korean (ko)
Other versions
KR20150091491A (ko
Inventor
에카테리나 바셋
바트 버링턴
휘 왕
케빈 엥
Original Assignee
제론 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/802,035 external-priority patent/US9200327B2/en
Application filed by 제론 코포레이션 filed Critical 제론 코포레이션
Priority to KR1020207031441A priority Critical patent/KR102348240B1/ko
Publication of KR20150091491A publication Critical patent/KR20150091491A/ko
Application granted granted Critical
Publication of KR102174763B1 publication Critical patent/KR102174763B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
KR1020157017235A 2012-11-30 2013-11-27 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커 Active KR102174763B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207031441A KR102348240B1 (ko) 2012-11-30 2013-11-27 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261732263P 2012-11-30 2012-11-30
US61/732,263 2012-11-30
US201361780851P 2013-03-13 2013-03-13
US61/780,851 2013-03-13
US13/802,035 US9200327B2 (en) 2012-11-30 2013-03-13 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US13/802,035 2013-03-13
US201361798478P 2013-03-15 2013-03-15
US61/798,478 2013-03-15
US201361809228P 2013-04-05 2013-04-05
US61/809,228 2013-04-05
PCT/US2013/072302 WO2014085632A1 (en) 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031441A Division KR102348240B1 (ko) 2012-11-30 2013-11-27 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커

Publications (2)

Publication Number Publication Date
KR20150091491A KR20150091491A (ko) 2015-08-11
KR102174763B1 true KR102174763B1 (ko) 2020-11-06

Family

ID=50828470

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157017235A Active KR102174763B1 (ko) 2012-11-30 2013-11-27 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커
KR1020217027659A Ceased KR20210112394A (ko) 2012-11-30 2013-11-27 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커
KR1020207031441A Active KR102348240B1 (ko) 2012-11-30 2013-11-27 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217027659A Ceased KR20210112394A (ko) 2012-11-30 2013-11-27 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커
KR1020207031441A Active KR102348240B1 (ko) 2012-11-30 2013-11-27 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커

Country Status (24)

Country Link
EP (4) EP3882355B1 (https=)
JP (2) JP6359028B2 (https=)
KR (3) KR102174763B1 (https=)
CN (2) CN104937110A (https=)
AU (4) AU2013352105B2 (https=)
BR (1) BR112015012507B1 (https=)
CA (1) CA2892445C (https=)
CY (1) CY1124140T1 (https=)
DK (2) DK3495495T3 (https=)
ES (3) ES2865446T3 (https=)
HR (2) HRP20181991T1 (https=)
HU (1) HUE054053T2 (https=)
IL (3) IL282112B (https=)
LT (2) LT2925889T (https=)
MX (1) MX362094B (https=)
NZ (2) NZ708654A (https=)
PL (2) PL3495495T3 (https=)
PT (2) PT3495495T (https=)
RS (1) RS61513B1 (https=)
SG (1) SG11201504209YA (https=)
SI (2) SI3495495T1 (https=)
SM (1) SMT202100142T1 (https=)
WO (1) WO2014085632A1 (https=)
ZA (2) ZA201900759B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3029154T (lt) 2008-10-17 2017-12-27 Geron Corporation Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JPWO2018207952A1 (ja) * 2017-05-12 2020-04-16 国立大学法人九州大学 発毛及び／又は育毛用組成物
KR102867725B1 (ko) 2017-07-28 2025-10-13 제론 코포레이션 골수형성이상 증후군의 치료 방법
US20200063214A1 (en) * 2018-07-31 2020-02-27 Geron Corporation Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor
GB201818792D0 (en) * 2018-11-19 2019-01-02 Telonostix Ltd Compounds for telomere length-related treatment of cancer
UA130012C2 (uk) 2018-11-29 2025-10-15 Джерон Корпорейшн Спосіб лікування мієлодиспластичного синдрому
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
CN114306602B (zh) * 2020-09-28 2024-06-11 中国科学院上海营养与健康研究所 靶向tert在调节皮肤及毛发色素中的应用
CN115463122B (zh) * 2022-08-16 2025-03-25 吕梁学院 一种增强盐霉素抗癌活性的方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
JPH11276182A (ja) * 1997-12-26 1999-10-12 Chugai Pharmaceut Co Ltd 逆転写酵素モチーフを有する新規遺伝子
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2474468C (en) 2002-01-31 2014-03-25 University Of Utah Amplifying repetitive nucleic acid sequences
US20040234961A1 (en) * 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
WO2004068110A2 (en) 2003-01-24 2004-08-12 University Of Utah Methods of predicting mortality risk by determining telomere length
CN100393209C (zh) 2003-09-09 2008-06-11 杰龙公司 用于端粒酶抑制的改性寡核苷酸
ME02933B (me) 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
CA2602562C (en) * 2005-03-25 2015-07-07 Alt Solutions, Inc. Modulation of telomere length in telomerase positive cells and cancer therapy
EP1876893B1 (en) * 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
LT3029154T (lt) * 2008-10-17 2017-12-27 Geron Corporation Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas
US9689028B2 (en) 2008-12-22 2017-06-27 University Of Utah Foundation Monochrome multiplex quantitative PCR
US20110207128A1 (en) 2010-02-16 2011-08-25 Cawthon Richard M Methods and kits for determining biological age and longevity based on gene expression profiles
ES2656958T3 (es) * 2011-03-28 2018-03-01 Geron Corporation Medición de la longitud de telómeros en muestras fijadas en formalina, embebidas en parafina (FFPE) por PCR cuantitativa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AACR, Cancer Res, 2011, 71(18 Suppl): Abstract nr C15 (2011.09.14-18.)*

Also Published As

Publication number Publication date
CY1124140T1 (el) 2022-05-27
BR112015012507A8 (pt) 2019-10-08
HK1215874A1 (en) 2016-09-23
KR102348240B1 (ko) 2022-01-10
CN111494629A (zh) 2020-08-07
SG11201504209YA (en) 2015-06-29
KR20150091491A (ko) 2015-08-11
EP3882355C0 (en) 2023-12-20
NZ748624A (en) 2020-08-28
EP3495495A1 (en) 2019-06-12
SI2925889T1 (sl) 2019-01-31
EP2925889A4 (en) 2016-06-15
EP2925889A1 (en) 2015-10-07
IL239035B (en) 2020-09-30
EP4497441A2 (en) 2025-01-29
AU2025201333B2 (en) 2025-10-16
ZA202101317B (en) 2023-03-29
AU2013352105B2 (en) 2019-09-19
DK2925889T3 (da) 2019-01-02
BR112015012507A2 (pt) 2017-07-11
EP2925889B1 (en) 2018-09-05
PT3495495T (pt) 2021-03-22
AU2022202808B2 (en) 2024-11-28
AU2019283840A1 (en) 2020-01-23
EP3495495B1 (en) 2020-12-23
IL270636B (en) 2021-04-29
ES2972330T3 (es) 2024-06-12
IL282112A (en) 2021-05-31
ES2703914T3 (es) 2019-03-13
SMT202100142T1 (it) 2021-05-07
LT2925889T (lt) 2018-12-27
ES2865446T3 (es) 2021-10-15
IL282112B (en) 2022-09-01
MX362094B (es) 2019-01-07
WO2014085632A1 (en) 2014-06-05
CA2892445C (en) 2022-06-28
ZA201900759B (en) 2020-10-28
KR20210112394A (ko) 2021-09-14
PT2925889T (pt) 2018-12-12
JP2016501523A (ja) 2016-01-21
KR20200128446A (ko) 2020-11-12
IL239035A0 (en) 2015-07-30
PL3495495T3 (pl) 2021-08-30
CN104937110A (zh) 2015-09-23
EP3882355A1 (en) 2021-09-22
JP2018099127A (ja) 2018-06-28
HUE054053T2 (hu) 2021-08-30
JP6359028B2 (ja) 2018-07-18
NZ708654A (en) 2020-04-24
AU2025201333A1 (en) 2025-03-20
AU2013352105A1 (en) 2015-06-18
RS61513B1 (sr) 2021-03-31
MX2015006538A (es) 2015-09-23
EP3882355B1 (en) 2023-12-20
PL2925889T3 (pl) 2019-02-28
LT3495495T (lt) 2021-02-25
CA2892445A1 (en) 2014-06-05
BR112015012507B1 (pt) 2023-03-07
SI3495495T1 (sl) 2021-07-30
HRP20210451T1 (hr) 2021-05-14
AU2022202808A1 (en) 2022-05-19
HRP20181991T1 (hr) 2019-03-08
DK3495495T3 (da) 2021-03-22

Similar Documents

Publication Publication Date Title
KR102174763B1 (ko) 텔로머라제 억제자로 세포 증식성 질환 치료용 진단 마커
US9951389B2 (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
DK2101789T3 (en) Combined telomerase inhibitor and gemcitabine for the treatment of cancer
JP2015525081A (ja) マイクロｒｎａのｍｉｒ−１５ファミリーの阻害剤
US20150344963A1 (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40062611A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40062611B (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40010121A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40010121B (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK40035697A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
HK1215874B (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6